Chlorpheniramine maleate is generally considered one of the safer antihistamine options during pregnancy, though no antihistamine has been proven completely risk-free. The American College of Obstetricians and Gynecologists (ACOG) includes chlorpheniramine on its short list of allergy medications considered safe for pregnant people. That said, the picture is more nuanced than a simple yes or no, especially depending on when during pregnancy you take it and how often.
What Major Medical Groups Say
ACOG specifically names chlorpheniramine and dexchlorpheniramine as allergy medications that studies support using during pregnancy. Newer antihistamines like cetirizine and loratadine are also listed as potentially safe alternatives. Under the older FDA pregnancy classification system, chlorpheniramine fell into Category B for standalone use, meaning animal studies showed no fetal harm but well-controlled human studies were lacking. No antihistamine has ever been classified in Category A, which would indicate proven safety from controlled human trials.
A large review in the Canadian Family Physician journal put it plainly: none of the first-generation antihistamines, including chlorpheniramine, has been reported to increase fetal risk when used at any point during pregnancy. A broader systematic review of the antihistamine literature described the overall evidence as “generally reassuring” regarding birth defects.
What the Research Shows About Birth Defects
The most detailed look at chlorpheniramine and specific birth defects comes from a large study published in the Journal of Allergy and Clinical Immunology: In Practice. Researchers examined previously suspected links between chlorpheniramine and eye defects, ear defects, spina bifida, and cleft lip. None of these associations held up statistically. All the confidence intervals crossed the threshold that would indicate a real effect, meaning the data could not confirm any of these risks were genuine.
However, the same study’s exploratory analysis (looking for new patterns rather than testing known hypotheses) did flag some associations that hadn’t been previously suggested. These included elevated rates of certain neural tube defects, a specific heart defect called tetralogy of Fallot, and a few other cardiovascular anomalies among babies whose mothers used chlorpheniramine in early pregnancy. These findings sound alarming on their own, but important context matters: when the researchers applied standard statistical corrections for testing many associations at once, every single one of these signals disappeared. That pattern is consistent with false positives, which are expected when you test dozens of possible links simultaneously.
The researchers themselves concluded that their findings “do not provide meaningful support” for previously suspected associations between antihistamines and major birth defects. The exploratory signals need further study before anyone should treat them as established risks.
First Trimester vs. Later Pregnancy
The first trimester is when organs form, so it’s the period of greatest concern with any medication. Most of the birth defect research focuses on this window. As noted above, the evidence for chlorpheniramine during this period is largely reassuring but not bulletproof. If you can manage allergy symptoms without medication during the first 12 weeks, that’s the most conservative approach. If your symptoms are severe enough to affect sleep, eating, or daily functioning, the risk-benefit balance may favor using chlorpheniramine at the lowest effective dose.
Later in pregnancy, the concern shifts from birth defects to how the drug might affect the baby near delivery. Chlorpheniramine is a first-generation antihistamine, which means it can cause drowsiness. In a follow-up study conducted by the Motherisk program, about 10% of mothers who used various antihistamines reported irritability and colic-like symptoms in their newborns, and 1.6% reported infant drowsiness. These effects are generally mild and temporary.
How It Compares to Other Antihistamines
You have several antihistamine options during pregnancy, and they differ in a few practical ways. Chlorpheniramine is a first-generation antihistamine. It works well for sneezing, runny nose, and itchy eyes, but it crosses into the brain more readily than newer options, which is why it causes drowsiness.
- Cetirizine and loratadine are second-generation antihistamines. Both are classified as Category B and cause less drowsiness. ACOG lists them as potentially safe during pregnancy, making them a reasonable alternative if sedation is a concern.
- Diphenhydramine is another first-generation option that’s widely used in pregnancy (it was the most commonly used antihistamine among study participants in the birth defect research). It causes significant drowsiness.
- Doxylamine is actually used as part of a prescription nausea treatment during pregnancy, so its safety profile is well studied. A meta-analysis of 16 cohort and 11 case-control studies found no association between doxylamine use and any birth defect, with a pooled relative risk of 0.95.
If you’re choosing between these options, the practical differences often come down to side effects rather than safety. Chlorpheniramine and diphenhydramine will make you sleepy. Loratadine and cetirizine generally won’t. All are considered reasonable choices during pregnancy.
Breastfeeding Considerations
If you’re also thinking ahead to after delivery, the LactMed database (maintained by the National Institutes of Health) states that small, occasional doses of chlorpheniramine in the range of 2 to 4 mg are acceptable during breastfeeding. Larger or more frequent doses could potentially affect the baby or reduce milk supply, especially if combined with a decongestant like pseudoephedrine or if taken before breastfeeding is well established.
There’s a specific biological reason for the milk supply concern. A related compound, dexchlorpheniramine, has been shown to lower baseline prolactin levels (the hormone that drives milk production) in postpartum women when given by injection at high doses. Notably, prolactin release triggered by actual breastfeeding was not affected. Whether the lower oral doses found in typical allergy pills have the same effect on prolactin hasn’t been studied, but caution in the early weeks of breastfeeding is reasonable.
Practical Guidance for Use
If you’re pregnant and considering chlorpheniramine for allergies or cold symptoms, a few practical points are worth keeping in mind. Use the lowest dose that controls your symptoms. Stick with plain chlorpheniramine rather than combination products that bundle it with decongestants, cough suppressants, or pain relievers, since each added ingredient carries its own risk profile. The combination product with codeine, for instance, carries a Category C rating and warnings about fetal harm based on animal data.
Non-drug approaches can also reduce how much medication you need. Saline nasal rinses, avoiding known allergens, and using air purifiers can take the edge off symptoms. When those measures aren’t enough, chlorpheniramine remains one of the longest-studied and most widely endorsed antihistamine options for use during pregnancy.